Patents Examined by Sarah Pihonak
  • Patent number: 11660281
    Abstract: The present invention includes a method of preventing and/or treating a fibrotic lung disease in a subject. In certain embodiments, the method comprises administering to the subject a thyroid receptor ?-agonist. The invention further comprises compositions useful within the invention, as well as kits comprising compositions useful within the invention.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 30, 2023
    Inventors: Naftali Kaminski, Guoying Yu, Argyrios Tzouvelekis
  • Patent number: 11648255
    Abstract: A new approach to treatment of hematological malignancies. A GAB1 inhibitor for use in a method of treatment of a hematological malignancy is disclosed. The GAB1 inhibitor may be administered alone, or simultaneously or sequentially with a BTK inhibitor to achieve a synergistic effect.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: May 16, 2023
    Inventors: Marek Mraz, Vaclav Seda, Laura Ondrisova
  • Patent number: 11649209
    Abstract: The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: May 16, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventor: Grahame Woollam
  • Patent number: 11648232
    Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 16, 2023
    Assignee: Axsome Malta Ltd.
    Inventors: Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
  • Patent number: 11643408
    Abstract: This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 9, 2023
    Assignee: Redx Pharma PLC
    Inventors: Inder Bhamra, Matilda Bingham, Richard Testar, Louise Sargent, Craig Donoghue
  • Patent number: 11642325
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: May 9, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 11642328
    Abstract: The application describes creatine or its derivatives, compositions comprising the same, and uses thereof for topical or systemic administration to treat pain, itch, or eczema, or inflammation associated with a cosmetic or medical condition, disorder or disease in a human subject, wherein the inflammation causes the pain, itch, or eczema. In addition, the application describes clinical use of these compounds and compositions which can reduce or eliminate erythema, edema and tissue distortions associated with inflammation.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: May 9, 2023
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Patent number: 11632971
    Abstract: There are provided methods of treating edible matter comprising applying a composition comprising performic acid to the edible matter or a substrate therefor. Other embodiments are also disclosed.
    Type: Grant
    Filed: February 17, 2019
    Date of Patent: April 25, 2023
    Assignee: SAVE FOODS LTD.
    Inventor: Nimrod Ben Yehuda
  • Patent number: 11622967
    Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: April 11, 2023
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Vijay Sidram Benade, Saivishal Daripelli, Pradeep Jayarajan, Jyothsna Ravula, Venkateswarlu Jasti
  • Patent number: 11617753
    Abstract: Disclosed herein are methods for treating an Ebola virus and inhibiting the transmission and propagation thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 4, 2023
    Assignees: OYAGEN, INC., The United States of America, as represented by the Secretary of Health and Human Services
    Inventors: Harold C. Smith, Ryan P. Bennett, Peter Jahrling
  • Patent number: 11617745
    Abstract: Provided are compositions and methods comprising a FOXO inhibitor for increasing proliferation of Lgr5+ cochlear cells, and related methods of treating hearing loss.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: April 4, 2023
    Assignee: Frequency Therapeutics, Inc.
    Inventors: Christopher Loose, Will McLean, Megan Harrison, Melissa Hill-Drzewi
  • Patent number: 11612576
    Abstract: The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: March 28, 2023
    Assignee: Thiogenesis Therapeutics, Inc.
    Inventors: Vincent P. Stanton, Jr., Patrice P. Rioux, Piotr Barski, Dariusz Witt
  • Patent number: 11607395
    Abstract: In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a ?-AR agonist and a peripherally acting ?-blocker (PABRA) to a patient in need thereof.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 21, 2023
    Assignee: Curasen Therapeutics, Inc.
    Inventors: Anthony P. Ford, Gabriel Vargas
  • Patent number: 11607408
    Abstract: The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 21, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Sandra Smieszek, Mihael H. Polymeropoulos
  • Patent number: 11602537
    Abstract: The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: March 14, 2023
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Joseph Prabahar Koilpillai, Sayuj Nath, Satish Patil, Somasundaram Muthuramalingam, Selvakumar Viruthagiri, Mohankumar Lakshmanan
  • Patent number: 11596631
    Abstract: The invention relates to inhibitors of CDK12 (cyclin-dependent kinase 12), and there use in the treatment or prevention of a disorder in a subject caused by the generation of repeat expansion transcripts.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 7, 2023
    Inventors: Christopher James Hayes, John David Brook, Ami Ketley
  • Patent number: 11590091
    Abstract: The present invention describes a pharmaceutical composition at a fixed dose of paracetamol and specifically amitriptyline supported by the pharmacological interaction and safety studies that show its synergy for the anti-allodynic, the mechanical anti-hypernociceptive effects and for the reduction of persistent pain, proportions, safety and neuroprotective capacity. This is aimed to the treatment of mixed pain due to cancer that can be incorporated as another option in the strategy of the WHO analgesic ladder at step 1 for the treatment of mild pain. However, it can also be included in higher steps associated with opioids for the treatment of pain of greater intensity and potentially decrease the escalation of its doses and adverse effects such as tolerance and hyperalgesia.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 28, 2023
    Inventors: Bárbara Beatriz Garrido Suárez, Addis Bellma Menéndez, Ania González Cortezón, Nilia De La Paz Martín-Viaña, Pedro Gilberto Bárzaga Fernández, Rolando Perdomo Morales, Alejandro Saúl Padrón Yaquis
  • Patent number: 11590133
    Abstract: The present invention provides various compositions and methods useful for the treatment of BRAF-mutant tumors, such as BRAFV600E-mutant tumors. In some embodiments such methods involve administration of three active agents—a RAF inhibitor, a MEK inhibitor, and an ERK inhibitor. The present invention also provides novel intermittent dosing regimens for these three active agents that maintain maximal anti-tumor efficacy while also minimizing toxicity.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 28, 2023
    Inventor: Piro Lito
  • Patent number: 11590105
    Abstract: Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: February 28, 2023
    Assignee: Sintetica S.A.
    Inventors: Augusto Mitidieri, Elisabetta Donati, Clara Bianchi, Barbara Piccagli
  • Patent number: 11590148
    Abstract: Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: February 28, 2023
    Assignee: EIRGEN PHARMA LTD.
    Inventors: Charles W. Bishop, Phillip Frost